Navigation Links
Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
Date:8/19/2007

sly reported, 44% (18 out of 41 patients evaluable for response). Of the 44%, 8 out of 14 patients were bortezomib-nave (57%); 7 out of 16 patients were bortezomib-pretreated patients (44%); and 3 out of 11 patients were bortezomib-refractory (27%). Responses in the bortezomib-refractory patients continue to show prolonged duration (at least 10 months at the time of data presentation at ASCO in June 2007) and meaningful reduction of serum/urinary M-protein (greater than 89%). The combination of tanespimycin and bortezomib was well-tolerated.

Kosan has been granted orphan drug designation for tanespimycin in multiple myeloma in both the US and European Union.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in multiple myeloma as monotherapy, in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a glo
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... SANTA ANA, Calif. , March 2, 2015 ... premier supplier of child-resistant packaging solutions for ... Co-Founder, Nicholas Kovacevich , has been nominated ... The Excellence in Entrepreneurship Award is ... entrepreneurial spirit – individuals who, by their creativity ...
(Date:3/2/2015)... NEW YORK , March 2, 2015 /PRNewswire/ ... LLC is investigating potential claims on behalf of ... ("Vitae Pharmaceuticals" or the "Company") (NasdaqGM: VTAE -News).  ... Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Vitae ...
(Date:3/2/2015)... March 2, 2015  CANTEL MEDICAL CORP. (NYSE: ... Krakauer , CEO, will be presenting at the Sidoti ... The formal presentation is scheduled for 2:00 PM ET ... Hotel, New York . In addition, ... Development, will be available for separate one-on-one meetings during ...
Breaking Medicine Technology:Kush Bottles CEO, Nicholas Kovacevich, Nominated for 2015 "Excellence in Entrepreneurship Award" 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vitae Pharmaceuticals, Inc. 2
... Pharmaceuticals, Inc. (Nasdaq: AUXL ) today announced ... 2011 Healthcare Conference during September 7-9, 2011 at the ... Financial Officer, is scheduled to present an overview of ... ET on Wednesday, September 7, 2011.   ...
... 2011 Wendy R. Fleishman ... Bernstein, LLP announced that Tiffany Littles, 33, of Jacksonville, Florida, ... for severe and lasting injuries caused by Bayer,s birth control ... prescription drug sold without adequate warnings about the risk of ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference 2Auxilium Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference 3Florida Woman Charges Life-Threatening Blood Clot Caused by Yaz Birth Control Drug According to Lieff Cabraser Heimann & Bernstein, LLP 2
(Date:3/2/2015)... (PRWEB) March 02, 2015 Doctors in ... be a better predictor of outcomes for people with ... read details of the new study on the ... at the University of Eastern Piedmont followed the cases ... pleurodesis treatment for excess lung fluid. , “Persistent ...
(Date:3/2/2015)... Angeles, CA (PRWEB) March 02, 2015 ... offering gum reshaping procedures. Gum reshaping can involve one or ... or to regenerate lost gum tissue for a more even ... dark gum line treatment that can permanently lighten ... his total smile approach, which involves a personalized treatment plan ...
(Date:3/2/2015)... 02, 2015 After a rigorous evaluation ... service, pricing and long-term strategy, Blood Centers of America ... choice for member centers’ testing needs. , BCA, which ... more than 30 percent of the U.S. blood supply, ... “BCA is committed to drive cost savings to members,” ...
(Date:3/2/2015)... 02, 2015 New York singer/songwriter ... be delivering a plenary address entitled Finding the ... Art of Healing and Recovery at this year’s ... Healthcare Executive Summit (BHES).     , With more than ... have been recorded by some of the biggest ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Over the ... acquisitions among leading vendors seeking to expand their geographic ... market is expected to reach $6.2 billion by 2019 ... North America including the U.S. and Canada and a ... devices. However developing regions such as Asia-Pacific including China ...
Breaking Medicine News(10 mins):Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3
... Steven Reinberg HealthDay Reporter , THURSDAY, April 12 ... partners are having babies than ever before, a new government ... 2010 were to such couples -- a threefold increase from ... Prevention found. "It,s thought that in births outside of ...
... In a study published in Nutrition Research , ... consumption with nutrient intake, diet quality and the prevalence ... in both children and adults. Consumers of OOHN, including ... pine nuts, pistachios and walnuts), had higher intakes of ...
... April 11, 2012 -- In a scientific paper ... researchers from SomaLogic and the University of Washington in ... assay technology to tissue samples. Working with both tumor ... lung cancer (NSCLC), they identified significant expression changes in ...
... , WEDNESDAY, April 11 (HealthDay News) -- The spouses ... and stroke, a new study suggests. Researchers said the ... health of caregivers. Using the national Swedish cancer registry ... heart disease and stroke increased by 13 to 29 percent ...
... , WEDNESDAY, April 11 (HealthDay News) -- Treatment-related ... their therapy has been completed, a new study says. ... and found that more than 60 percent of them ... years after their diagnosis, and 30 percent had at ...
... , WEDNESDAY, April 11 (HealthDay News) -- ... people in the United States who lived in state-regulated ... federal report. People who live in residential care ... supportive services because they can,t live independently but generally ...
Cached Medicine News:Health News:More Unmarried Couples Having Babies: CDC 2Health News:Out-of-hand tree nut consumption associated with better diet quality in children and adults 2Health News:SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples 2Health News:Breast Cancer Treatment Side Effects May Last for Years 2